What's your name?
What’s your company and describe your role?
I am the Chair of Biochemistry in Trinity College Dublin, and co-founder of Opsona Therapeutics and Inflazome, two biotech companies that are spinouts from my Trinity lab.
How long have you held the position?
Opsona since 2004, Inflazome since 2016
What are your day to day responsibilities?
I am the Chief Scientific Officer in both companies, which means I look after the scientific aspects of what we do.
What is your professional background?
I have a degree in Natural Sciences from Trinity College Dublin and a PhD in Pharmacology from the University of London. My area of expertise is immunology.
Tell me about yourself away from work?
I play piano and guitar and I love being at sea (privately, not professionally).
Tell us something very few people know about you?
I have just completed a course in creative writing with Pat Boran at the Irish Writers Centre
You are speaking at iQuest’s 2017 Biopharma Summit. What are you speaking about?
I will speak about the process of drug discovery, from science to patient, specifically in the area of inflammatory diseases.
What challenges do you see for the biopharma industry?
It’s a great time for the industry as all the great science that’s been done over the past 20 years is starting to yield in terms of new medicines for diseases where the need is great, including inflammatory diseases and cancer. The challenge is the cost of developing these new drugs and getting them to the patients who need them.
Where do you see the industry in 10 years time?
Booming – with the ageing population the need for the new medicines will grow and grow.